Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 CHICAGO / May 20, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for its first in-person and virtual analyst and investor day in New York... Read More

Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3 rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO / May 08, 2025 / Business Wire / Xeris Biopharma Holdings, Inc . (Nasdaq: XERS), a fast-growing biopharmaceutical... Read More

CHICAGO / May 01, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will... Read More

CHICAGO / Mar 28, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced changes to its board of directors. Ricki Fairley has resigned from the board in light of other commitments, effective immediately. The Board of Directors has... Read More

First concentrated, ready-to-dilute liquid glucagon available for growing procedural gastroenterology market American Regent to commercialize GVOKE VialDx™ Availability is expected in the third quarter of 2025 CHICAGO / Mar 17, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative... Read More

Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting... Read More

Conference call and webcast at 8:30am ET CHICAGO / Feb 27, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2024 financial results and provide 2025 financial... Read More

Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire CHICAGO / Feb 24, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken... Read More

CHICAGO / Feb 05, 2025 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 1x1... Read More

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va. , Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association ® (ADA) and Xeris Pharmaceuticals ® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic... Read More

Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 CHICAGO / Jan 10, 2025 / Business Wire... Read More

CHICAGO / Nov 26, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024... Read More

Achieved record total revenue of $54.3M including record product revenue of $52.9M Product revenue increased 27% versus prior year and 14% over the prior quarter Ended Q3 with $69.4M in cash, cash equivalents and short-term investments Raises full-year guidance of total net revenue to $198M-$202M and tightens year-end cash to $68M-$72M Hosting conference call and webcast today at 8:30 a.m. ET CHICAGO / Nov 08, 2024 /... Read More

Conference call and webcast at 8:30am ET CHICAGO / Oct 31, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets... Read More

CHICAGO / Oct 04, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 364,000 shares of its common... Read More

CHICAGO / Aug 22, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will take part in the following events: 2024 Wells Fargo Healthcare Conference, Boston, MA Meetings only on September 4,... Read More

Achieved revenue of $48.1M including record product revenue of $46.5M Total revenues increased 18% over the prior quarter and 26% over the same period prior year Ended Q2 with $77.6M in cash, cash equivalents and short-term investments Tightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cash balance to $60M-$75M John Shannon appointed CEO and Kevin McCulloch promoted to President and COO per the... Read More

Conference call and webcast at 8:30am ET CHICAGO / Jul 25, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets... Read More

John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 ’24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year... Read More

CHICAGO / Jul 03, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 196,000 shares of its common... Read More

In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-related adverse events and liver test abnormalities. The SONICS study previously showed that Recorlev treatment was effective at normalizing... Read More

XeriSol™ formulation enabled predictable bioavailability and sustained levels of levothyroxine in a once-weekly subcutaneous presentation Once-weekly SC levothyroxine (XP-8121) participants normalized TSH/T4 levels using 45% less drug than would be needed for their daily oral dose on a weekly basis Data established an average once-weekly SC dose of XP-8121 and confirmed previous Phase 1 study of a 4X target dose conversion... Read More

CHICAGO / May 30, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern... Read More

Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab Announced an exclusive worldwide agreement with Beta Bionics for development of a new XeriSol™... Read More

For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems CHICAGO / May 06, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has... Read More

Conference call and webcast at 8:30am ET CHICAGO / May 02, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets... Read More

CHICAGO / Apr 03, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common... Read More

CHICAGO / Apr 02, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday,... Read More

Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achieving cash flow positive of over $6M in the fourth quarter Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab... Read More

Improves cost of capital Increases committed capital to a total facility size of $215M CHICAGO / Mar 06, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it has entered into an amended and restated senior secured term loan... Read More

CHICAGO / Feb 28, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6,... Read More

CHICAGO / Feb 05, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on... Read More

CHICAGO / Jan 10, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of... Read More

CHICAGO / Jan 05, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on January 2, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 130,000 shares of its common... Read More

Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M Company to report Q4 and FY 2023 financial results on or about March 6, 2024 CHICAGO / Jan 04, 2024 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq:... Read More

CHICAGO / Dec 27, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday,... Read More

Achieved record revenue of $48.3M – a 27% increase from prior quarter, and a 63% increase from same period prior year Tightens full-year 2023 revenue guidance from $155M-$165M to $160M-$165M Ended Q3 with $66.0M in cash, cash equivalents and short-term investments and remains on track to achieve cash flow breakeven in the fourth quarter Extended maturity of approximately two-thirds of 2025 Convertible Senior Notes to 2028... Read More

Raises year-end cash, cash equivalents, and short-term investment guidance from $55M-$65M to $65M-$70M 2023 Cash Utilization expected to be $52M-$57M Tightens 2023 Total Revenue guidance from $145M-$165M to $155M-$165M Received $6M milestone payment for successfully formulating sub-cutaneous TEPEZZA ® Q3 2023 financial results conference call and webcast November 9, 2023 at 8:30 a.m. ET CHICAGO / Oct 16, 2023 / Business Wire... Read More

CHICAGO / Sep 27, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that on September 26, 2023, it and Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris (the “Guarantor”), entered into separate, privately... Read More

CHICAGO / Sep 14, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming 2023 Cantor Global Healthcare Conference in New York, NY on... Read More

CHICAGO / Aug 28, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25 th Annual Global Investment Conference on Monday,... Read More

Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utilization of $57M-$67M; 2023 year-end cash balance of $55M-$65M Remains on track to achieve cash flow breakeven by year-end 2023 Hosting conference call and... Read More

Conference call and webcast at 8:30am ET CHICAGO / Aug 01, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2023 financial results before the open of the U.S. financial markets... Read More

Updated guidelines recognize the benefits of ready-to-use glucagon Protecting all people with diabetes at risk of severe hypoglycemia remains the goal CHICAGO / Jul 31, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that... Read More

Novel formulation of levothyroxine sodium (SC injection) to potentially mitigate many of the challenges associated with oral formulations of levothyroxine. Phase 2 study to establish the average once-weekly dose, accrue additional safety data, and facilitate a future Phase 3 program CHICAGO / Jun 21, 2023 / Business Wire / Xeris Biopharma Holdings, Inc . (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed... Read More

CHICAGO / Jun 01, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time.... Read More

Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M; cash utilization from operating activities of $57M-$77M; year-end cash, cash equivalents, and short-term investments of $45M-$65M Announced research collaboration and option agreement with Regeneron for... Read More

Conference call and webcast at 8:30am ET CHICAGO / May 02, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2023 financial results before the open of the U.S. financial markets... Read More

CHICAGO / Apr 18, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘ METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN... Read More

CHICAGO / Mar 30, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, today announced that it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the... Read More

CHICAGO / Mar 29, 2023 / Business Wire / Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapeutic areas, appointed Ricki Fairley to its Board of Directors, increasing the size of... Read More

CHICAGO / Mar 08, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year 2022 and provided 2023 financial guidance. “Xeris had another record-breaking quarter to finish 2022... Read More

CHICAGO / Feb 23, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, March 8,... Read More

CHICAGO / Feb 02, 2023 / Business Wire / Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023,... Read More

CHICAGO / Jan 30, 2023 / Business Wire / Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals, Inc., orphan-drug exclusivity (ODE) for Recorlev® (levoketoconazole)... Read More

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time. To... Read More

Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M Company to report Q4 and FY 2022 financial results on or about March 8, 2023 Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products... Read More

Targeting initiation of a Phase II study by 2H 2023 CHICAGO--( BUSINESS WIRE )-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a... Read More

Xeris to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into a research collaboration and option agreement with Horizon... Read More